Abstract
Introduction: In the lower urinary tract (LUT) several members of the TRP superfamily are involved in nociception and mechanosensory transduction. Animal studies have suggested a therapeutic potential of some of these channels, including TRPV1, TRPV4, TRPM8, TRPA1, and TRPM4, for treatment of bladder over- and underactivity and bladder pain disorders, but translation of this information to clinical application has been slow. Areas covered: An update on and discussion of current information on the potential clinical use of TRP channel agonists/antagonists in the treatment of different types of bladder dysfunction. The electronic databases PubMed and Scopus were used to identify relevant clinical and animal studies. Expert opinion: The therapeutic effect of TRPV1 channel desensitizing agonists (capsaicin, resiniferatoxin, given intravesically) has been convincingly demonstrated in some forms of bladder overactivity. However, so far, the potential of any of the small-molecule TRP channel blockers developed for non-bladder indications and tested in early human trials for safety has not been explored clinically in LUT dysfunction. The adverse effects of hyperthermia and reduction of noxious heat sensation of the first generation TRPV1 blockers have delayed development. Despite lack of translational information, TRP channels remain interesting targets for future LUT drugs.
TY - JOUR
T1 - Agents in early development for treatment of bladder dysfunction - promise of drugs acting at TRP channels?
A1 - Andersson,Karl-Erik,
Y1 - 2019/08/14/
PY - 2019/8/11/pubmed
PY - 2019/10/28/medline
PY - 2019/8/11/entrez
KW - Lower urinary tract
KW - TRPA1
KW - TRPM4
KW - TRPM8
KW - TRPV1
KW - TRPV4
KW - bladder pain
KW - overactive bladder
KW - underactive bladder
SP - 749
EP - 755
JF - Expert opinion on investigational drugs
JO - Expert Opin Investig Drugs
VL - 28
IS - 9
N2 - Introduction: In the lower urinary tract (LUT) several members of the TRP superfamily are involved in nociception and mechanosensory transduction. Animal studies have suggested a therapeutic potential of some of these channels, including TRPV1, TRPV4, TRPM8, TRPA1, and TRPM4, for treatment of bladder over- and underactivity and bladder pain disorders, but translation of this information to clinical application has been slow. Areas covered: An update on and discussion of current information on the potential clinical use of TRP channel agonists/antagonists in the treatment of different types of bladder dysfunction. The electronic databases PubMed and Scopus were used to identify relevant clinical and animal studies. Expert opinion: The therapeutic effect of TRPV1 channel desensitizing agonists (capsaicin, resiniferatoxin, given intravesically) has been convincingly demonstrated in some forms of bladder overactivity. However, so far, the potential of any of the small-molecule TRP channel blockers developed for non-bladder indications and tested in early human trials for safety has not been explored clinically in LUT dysfunction. The adverse effects of hyperthermia and reduction of noxious heat sensation of the first generation TRPV1 blockers have delayed development. Despite lack of translational information, TRP channels remain interesting targets for future LUT drugs.
SN - 1744-7658
UR - https://www.unboundmedicine.com/medline/citation/31399015/Agents_in_early_development_for_treatment_of_bladder_dysfunction___promise_of_drugs_acting_at_TRP_channels
L2 - https://www.tandfonline.com/doi/full/10.1080/13543784.2019.1654994
DB - PRIME
DP - Unbound Medicine
ER -
